DR.

MUHAMMAD MUSHTAQ
GM MKG & SALES
 VEMTIX
MARKETING &
SALES PLAN 2020

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
 Objectives
• Introduction to Product
• Executive Summary IMS Data
• IMS Data
• MIP Data
• Internal Prospecting Data
• Customer Behavior Identification
• SWOT Analysis
• Marketing Objectives
• Positioning
• Pre-Launch Activities
• Launch Activities
• Post-Launch Activities
3 MUSHTAQ
DR. MUHAMMAD
GM MKG & SALES
 Ondansetron Target Indications

Nausea and Vomiting in

• Chemotherapy & Radiotherapy

• Viral Hepatitis
• Gastroenteritis and colitis infections
• Pregnancy and Hyperemesis Gravidarum (HG)
• Postoperative Cases
• General Conditions
• Cholecystitis

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
 Treatment Options

• Domperidone (Motilium)
• Metoclopramide (Maxolon)
• Dimenhydrinate (Gravinate)
• Ondansetron
• L-hyoscine (Buscopan)
• Prochloperazine (Stemetil)

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
 IMS Flow Chart

TC1: ALIMENTARY T.& METABOLISM(A)

UNITS VALUE
666.2 M 110.9 B

TC2: ANTIEMETICS-ANTINAUSEANTS (A04)

UNITS VALUE
11.3 M 1.3 B

TC3: SEROT ANTAG A-EMET+A-NAUS(A04A1) UNITS VALUE

2.5 M 500 M

UNITS VALUE
TC4: ONDANSETRON
2.5 M 500 M

7 MUSHTAQ
DR. MUHAMMAD
GM MKG & SALES
 Different Anti-Emetics & Anti-Nauseatics Units
0.95 M
1.3 M IMS –MAT – NOV- 2018-2019

8%
5%

0.5 M
-0.1 M -0.2 M
0.1 M
9% 0.5 M
-3% 1.2 M
5%
-5%
25% 151%

Domperidon Dimenhydrinate Metoclopramide Ondansetron

2019 20686902 5750314 4044458 2594063
2018 19736067 5938994 4246545 2086010
2017 18351622 5449841 4063475 831990
DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
 Different Anti-Emetics & Anti-Nauseatics Value
346 M
IMS –MAT – NOV- 2018-2019

136 M

8%
19%

14 M 33 M
147 M
-15 M 24 M
140
M
4% 8%
-4% 10% 42% 66%

Domperidone Dimenhydrinate Metoclopramide Ondansetron

2019 2195421732 359261110 349814209 500607076
2018 1849356173 374654264 317073716 353426962
2017 1712603794 360436621 293410964 213000778
DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
 ONDANSETRON
UNIT- MILN
VALUE- MILN

0.5 M
147 M
1.2 M
140 M

151%
66%

24% 42%

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
 TOP BRANDS ONDANSETRON
459,930 UNITS

102
M

165%

23%

20,82
36,453 1,821 (13278) 422 2312
0
5,546 (19946) (7546) 0
7,625 1,897

999% -50%
ONSET ONSERON
999% ADOSETRON ZOFRAN22% -47%
ONDASENTRON DANSET DOSTON
375% -58% 6% 999%
2019 2491743 478%
44078 26366 18%
12198 9501 7865 2312 000
2018 2031813 7625 5546 10377 22779 7443 0
2017 765694 0 0 8480 42743 14989 0
DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
 TOP BRANDS ONDANSETRON
104 M VALUE(M)

175 M

150%

36%

16 M 28 M 6M (6 M) (5 M) 5M

8M (9 M) (40 M) 0
3M 3M

999% 25% -82%

ONSET ONSERON
999% ADOSETRON ZOFRAN -47%
ONDASENTRON DANSET DOSTON
-58% -54% 999%
2019 394.5 900% 15%42.9
483%19.7 30.6 4.1 3.7 4.7 000
2018 290.5 3.3 3 37.3 10 8.2 0
2017 116 0 0 29.8 18.7 47.9 0
DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
 TOP BRANDS ONDANSETRON UNITS MKT
SHARE

ZOFRAN; 10377; 0%
ZOFRAN; 12198; 0%
ONDANSENTRON; 9501; 0% ONDANSENTRON; 22779; 1%
DANSET; 7865; 0% DANSET; 7443; 0%
ADOSETRON; 26366; 1% ADOSETRON; 5546; 0%

DOSTON; 2312; 0%
ONSERON; 44078; 2% ONSERON; 7625; 0%

165%
23 ONSET; 2031813; 97%
ONSET; 2491743; 96%
%
2019 2018

DANSET; 14989; 2%
ONDANSENTRON; 42743; 5%
ZOFRA
N;
8480;
1%

ONSET; 765694; 92%

2017
DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
 TOP BRANDS ONDANSETRON VALUE(M) MKT
SHARE
ZOFRAN;
ZOFRAN; 37.3; 11%
42.9; 9% DANSET; 3.7; 1%
ONDANSENTRON; 10; 3% DANSET; 8.2; 2%
ADOSETR ONDANSENTRON; 4.1; 1% ADOSETRO
ON; 30.6; N; 3; 1%
6%
DOSTON; 4.7; 1%

ON- ONSERON;
SERON; 3.3; 1%
19.7; 4%
ONSET;
ONSET;
150%
394.5;
79% 290.5;
82%
36 2018
2019 %
DANSE
T; 47.9;
23%
ON-
DANSE
NTRON
; 18.7;
9%

ON-
SET;
ZOFRA 116;
N;
29.8; 55%
14%

2017
DR. MUHAMMAD MUSHTAQ
IMS –MAT – NOV- 2019 GM MKG & SALES
 ONDANSETRON STRENGTHS WISE SHARE

-9% -
4112; 0% 2.6; 1% 60%
115500; 4% 89%
-16%
20; 4%
42%
27%

8MG 8MG
2,474,451, 95% 477.9, 95%

UNITS VALUE
2,594,063 500,607,076

8MG 4MG 2MG DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
 ONDANSETRON 8 mg Injectable & Tablets WISE SHARE

35% 45% 8MG

TABLE
24% , 39%
TS; 225,
75544 TABLE
9; TS; 483,
31% 25248 504,
0327; 47%
IN- 53%
JECTA
BLE;
17190
02;
69%

UNITS VALUE
24,74,451 477,963,831

INJECTABLE TABLETS DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
Ondansetron IMS-Data Inferences

• Only one brand is enjoying MKT.

• Equal opportunity is lying both in Tablets and Injections.

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
Ondansetron MIP Data

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
Rx- spread in different indications
APP FORM LEVEL I MAT ~ 06/2017 MAT ~ 06/2018 MAT ~ 06/2019

RX-PRESC. RX-PRESC. RX-PRESC.

DIAG III

SELECTED TOTAL 429,307 441,037 813,100

NAUSEA AND VOMITING 352,611 294,679 448,863

EXCESS VOMIT PREG 33,448 99,789 99,667

SUPER NORM PREG 7,710 2,573 0

GASTRO & COLIT INF UNSP 5,137 7,998 170,340

DENGUE FEVER 5,137 0 0

DORSALGIA 4,659 0 0

GASTRITIS AND DUODENITIS 3,744 15,410 9,057

OTH DIS OF STMCH/DUODEN 3,090 2,035 10,801

CA OF COLON 1,583 1,056 792

CA OF BREAST 1,320 792 5,278

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
Rx- spread in different indications
CA OF BREAST; CA OF COLON;
5278; 1% 1056; 0% CA OF BREAST;
2019
CA OF COLON; 792; 0%

2018
792; 0%
OTH DIS OF OTH DIS OF
STMCH/
DUODEN;
STMCH/DUO-
10801; 1% DEN; 2035; 0%
GASTRITIS GASTRITIS
AND DUO- AND DUO-
DENITIS; 9057; DENITIS;
1%
NAUSEA AND VOMIT- 15410; 4%
ING; 448863; 60%
NAUSEA AND VOMIT-
ING; 294679; 69%

EXCESS VOMIT PREG;

GASTRO & 99789; 24%
GASTRO &
COLIT INF COLIT INF
UNSP; 170340; UNSP; 7998;
23% EXCESS VOMIT PREG; 99667; 2%
13%
CA OF COLON; CA OF BREAST; SUPER NORM
1583; 0% 1320; 0% PREG; 2573; 1%
OTH DIS OF
STMCH/DUO-
DEN; 3090; 1%
GASTRITIS
AND DUO-
DENITIS; 3744;
1%

DORSALGIA;
4659; 1%
DENGUE
FEVER; 5137; NAUSEA AND VOMIT-
1% ING; 352611; 84%
GASTRO &
COLITEXCESS
INF VOMIT
UNSP;PREG;
5137;33448;
1% 8%

SUPER NORM
PREG; 7710; 2% 2017 DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
Specialty Rx Share
SURG.; 2940; GASTRO; 1154; GASTRO; 1732;
0% 0% 0%
SURG.; 5880; 1%

PHYSICIAN;
40695; 5% PHYSICIAN;
14243; 3%

RMO.; 84664;
11% G.P.; 492507;
61% RMO.; 55871; G.P.; 210245;
13% 48%

ONCO; 86295;
11% ONCO; 77850;
18%
GYNAE.; 95200;
12% GYNAE.; 69470; 16%
GASTRO; 1443;
2019 SURG.; 5880; 1% 0% 2018
PHYSICIAN;
16278; 4%

ONCO; 72836;
17%

G.P.; 287411;
67%
GYNAE.; 43740;
10%

2017
DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
Regional Rx Share

LAHORE;
244617;
75%
SINDH;
9178; 2% MULTAN; 92892; MULTAN;
19% 34721; 11%
LAHORE; SINDH; 264;
316362; 0%
65%

KARACHI; KARACHI;
38224; 8% 21394; 7%

FAISAL- FAISAL-
ABAD; ABAD;
27966; 6% 27074; 8% 2018
2019
MULTAN;
29322; 10%
LAHORE;
SINDH; 229969;
1056; 0% 77%

KARACHI;
29859; 10%

FAISAL-
ABAD; 7530;
3%
2017 DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
 Inferences-MIP Data TAB 8mg

• Priority indications
• NAUSEA AND VOMITING 60%,
• GASTRO & COLIT INF UNSP 23%
• EXCESS VOMIT PREG 13%
• Major Segments are
• GP 61%, GYN 12%, Oncology 11%, RMO 11%s & PHY 5%
• Top Regions Lahore, Multan, KHI & Faisalabad, RWP & PSH

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
Ondansetron MIP Data

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
 RX-PRESC. RX-PRESC. RX-PRESC.
APP FORM LEVEL I MAT ~ 06/2017 MAT ~ 06/2018 MAT ~ 06/2019
SELECTED TOTAL 574,973 923,148 1,270,906
PARENTERAL ORDINARY 574,973 923,148 1,270,379
NAUSEA AND VOMITING 315,155 598,858 524,288
GASTRO & COLIT INF UNSP 19,880 33,212 246,514
CA OF BREAST 56,211 51,724 69,142
UNSP VIRAL HEPATITIS 0 4,138 59,272
CA OF OVARY 24,543 33,515 38,793
EXCESS VOMIT PREG 2,573 14,439 36,021
PNEUMONIA ORGISM UNSP 0 0 21,933
CA OF BRONCHUS AND LUNG 9,500 13,459 15,570
CHOLERA 0 0 13,046
CHOLECYSTITIS 2,940 5,137 12,308
TYPHOID/PARATYPHOID FEV 0 0 12,308
CA BONE ART CRT OTH/UNSP 6,070 3,959 12,139
CA OF GALLBLADDER 3,167 5,278 10,292
OESOPHAGEAL VARICES 0 0 10,022
HODGKIN'S LYMPHOMA 5,806 6,597 8,709
OTH/UNSPEC TYPES OF NHL 3,695 5,014 8,709
CA OF OESOPHAGUS 8,709 5,806 8,445
CA OF COLON 6,070 8,709 8,445
CA OF BLADDER 4,222 3,431 8,445
CA OTH/UNSP PARTS TONGUE 7,389 8,973 7,653
CA OTH ILL DEF SITES 4,750 6,070 7,389
CA OTH CONN/SOFT TISSUE 5,806 3,959 7,125
CA OF PANCREAS 3,431 4,222 6,334
CA OF STOMACH 1,056 3,959 6,070
AMOEBIASIS 0 5,137 5,137
ACUTE HEPATITIS A 0 2,035 5,137
ACUTE TONSILLITIS 0 0 5,137
OTH INFLAMM LIVER DIS 0 0 5,137
FEVER OTH & UNKNOW ORIG 0 0 5,137
OTH SURG F/U 0 0 4,975
ACUTE APPENDICITIS 0 2,940 4,885
CA LVR/INTRAHEP BLE DCTS 1,847 2,639 4,750
CA OF CORPUS UTERI 1,847 2,375 4,486
CA OF RECTUM 4,486 3,431 4,222 DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
CA OF TESTIS 4,222 2,111 4,222
Rx- spread in different indications
PNEUMONIA ORGISM UNSP;
21933; 2%
EXCESS VOMIT
PREG; 36021; 2019
4%
EXCESS VOMIT
2018
PREG; 14439;
UNSP VIRAL 2%
HEPATITIS;
59272; 6%
UNSP VIRAL
HEPATITIS;
4138; 1%
CA OF BREAST;
69142; 7% NAUSEA AND VOMIT-
ING; 524288; 55%
CA OF BREAST;
51724; 7% NAUSEA AND VOMIT-
GASTRO & COLIT INF ING; 598858; 85%
UNSP; 246514; 26%

GASTRO &
COLIT INF
UNSP; 33212;
5%

2017
EXCESS VOMIT
PREG; 2573; 1%

NAUSEA AND VOMIT-

ING; 315155; 80%
CA OF BREAST;
56211; 14%

GASTRO &
COLIT INF DR. MUHAMMAD MUSHTAQ
UNSP; 19880; GM MKG & SALES
5%
 Specialty Rx Share
GASTR; 1732; GASTR; 3752;
0% 0%

SURG; 14700;
1% SURG;
44101; 5%
PHY; 30521; G.P.; 732079; G.P.; 579948;
3% 60% 64%
PHY; 14243; RMO.;
RMO.; 89384; 24860; 3%
7% 2%
GYN; 41167;
3% GYN; 10292;
1%
ONCO;
229593; 25%
ONCO;
302429; 25%

GASTR; 3175;
2019 1% 2019
SURG;
35281; 6%

RMO.; 3345; G.P.; 324559;

1% 56%

GYN; 5146;
1%

ONCO;
203467; 35%

DR. MUHAMMAD MUSHTAQ

2019 GM MKG & SALES
Regional Rx Share
SINDH; MULTAN;
4750; 1% MULTAN; 171205; 124672;
25% 21%

SINDH; 792;
KARACHI; 0%
165916;
25%
LAHORE;
314195;
LAHORE; KARACHI; 54%
262489; 100431;
39% 17%
FAISAL-
ABAD; FAISAL-
67436; 10% ABAD;
45955; 8%

2019 2018
MULTAN;
4628; 1% LAHORE;
SINDH; 262191;
1056; 0% 70%

KARACHI;
79434; 21%

FAISAL-
ABAD;
28262; 8%
2017 DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
Inferences-MIP Data Injectable 8mg

• Rx are increasing continuously every year.

• NAUSEA AND VOMITING & GASTRO & COLIT INF UNSP are major indications
• In 2019 GASTRO & COLIT INF prescriptions increases rapidly among Gastro segment
• Top Regions Lahore, Multan, KHI, FSD

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
 INTERNAL
PROSPECTING DATA

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
 PROSPECTING DATA
INJECTABLE+ORAL

GP; 6252; 6% ONCOLOGY; 11163; 10%

SURGERY;
ER; 28702; 26% 21383; 19%

GASTRO; 21584; GYNAE; 20817;

20%Tab, 19%
Inj.

GRAND TOTAL 42,759 18,902 DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
 PROSPECTING INJECTABLE & TABLETS 8MG
DATA

INJECTABLE TABLETS

ONCOLOGY; 3908;
GP; 2072; 6% 11%
ONCOLOGY; 7255;
GP; 4180; 6% 11%
ER; 9404; SURGERY;
25% 6325; 17%
ER; 12298;
19% SURGERY;
15058; 23%

GASTRO;
GYNAE; 8606; 23%
13979; GYNAE;
GASTRO; 21% 6838; 18%
12978; 20%

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
PROSPECTING TOP REGIONS
INJECTABLE+TABLETS

RWP; 13998; 18%

LAHORE; 21416;
27%
PSH; 5873; 7%

KHI, 6870
9% MUX; 20572; 26%
FSD, 9730
12%

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
Summary
Internal Prospecting Specialty worth Analysis

SEGMENTS INJ TAB

ONCO/HOSPITALS
207 135
ONCO/CLININCS
71 22
SUR
36 15
GYN
31 16
GASTRO
31 28
PRIVATE ER
62 27
GPs
17 8

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
TOP PRESCRIBERS

35 MUSHTAQ
DR. MUHAMMAD
GM MKG & SALES
Internal Prospecting Conclusion

Major focused segments are: Top Business Regions:

• Oncology • LHR
• ERs (Private& Govt) • MUX
• KHI
• Gastroenterology • FSD
• Gynae • RWP
• Surgery • PSW
• GPs

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
Customer Behavior Identification
Survey

37 MUSHTAQ
DR. MUHAMMAD
GM MKG & SALES
Specialties selection

ONCOLOGY; 9; 12%

GPs, 25
, 34% GSTRO;
15; 20%

GYN; 14; 19%

SURG; 11;
15%
DR. MUHAMMAD MUSHTAQ
GM MKG & SALES
1st Line Vs. 2nd Line
1ST LINE; 15;
15%

2ND LINE; 85; 85%

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
Limitations/Challenges

AWARENESS,
19,
ECONOMY, 15,
33%
41%

SAFETY, 12, 26%

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
 VEMTIX

Weakness
Strength
1. Small team VS 3 Teams
1. Strong Corporate Image in Gyn & Gastro
2. New enterant in Oncology
2. Easy name to memorize

SWOT
Opportunity Threats
1. Growing market by 42%
2. Less Competitive MKT 1. One brand is holding MKT share since long
time
3. Un-explored MKT
2. KOLs ..Long Association with One brand
3. Reason to Change….No USP

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
 Marketing objectives

• To establish VEMTIX as a 1st Line

Qualitative treatment of Nausea & Vomiting by
creating awareness among HCPs.

• To Make 2nd largest brand in 1st year of

launch with value of 87Mio & 15% MKT
Quantitative Share.

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
Positioning

To establish VEMTIX among Oncologist, Surgeons,

Gynecologist, Gastroenterologist & GPs as a first line
choice with safe and capable control in Patients with
Nausea & Vomiting with fast restoration of patients
conditions as compared to other antiemetic.

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
 Target Audience
Major focused segments are:
• Oncology(All in TMs Territory) • 5
• ERs (Private& Govt) • 5
• Gastroenterology • 10
• Gynae • 10
• GPs • 10
• Surgery • 5

TOTAL DOCTOR = 45/TM

NATIONAL =2790

DR. MUHAMMAD MUSHTAQ

GM MKG & SALES
Pre-Launch Activities
PSG-Peshawar
• VEMTIX Teasing
• Drone Camera
• Drone Mascot
• VEMTIX Branading Bubble Gum(Xylitol)

45 MUSHTAQ
DR. MUHAMMAD
GM MKG & SALES
 Pre-Launch Activities

• Pre-Launch Poster…… 30 Mar to 04-02-2019

• Chemists Letter…..23 to 28 March-2019
• Teasers Cards ……30 Mar to 04-02-2019
• Post-Launch Posters… 8 Apr to 15 Apr-2019

Teaser Card Pg-2 Post Launch Poster

Pre Launch Poster Teaser Card Pg-1
Marketing Activities

48 MUSHTAQ
DR. MUHAMMAD
GM MKG & SALES
 Pre-Launch Hunting

• To Establish advocacy pool of Top class Consultants

• 16-20 Top class (Station wise)
• LHR-4, MTN-2, FSD-2 , KHI-4, RWP-4 & PSH-2
• Oncology, Gastro/PHY and GYN
 Launching Activity
VEMTIX Cake Cutting

Institutions / Wards Clinics

• VEMTIX Launching Cake Cutting • VEMTIX Launching Cake Cutting
• Total 64 Wards and HODs (4 • Total 310 Drs (5/TM)
Wards/District) • GASTRO
• GASTRO • GYN
• GYN • ONCO
• ONCO • SURG
• SURG
 VEMTIX Launch symposia
• Total Symposia 24 (All Big Cities-12)
• 2 Symposia / city
• ONCO + GASTRO/PHY + SURG
• GYN + GP (Remaining Drs.)
• Total 1200 Drs
• Presentation by VEMTIX NV Management Forum Consultant
• Jun – Dec-2020
ONCOLOGIST DEVELOPMENT PLAN

• Total = 100 Consultants at National level.

• HODs or Professors of the Oncology Wards
• Personalize gifts will be delivered for consecutive 3 months

ONCOLOGY
ONCOLOGY
HOSPITAL DRs 295
PRIVATE DRs 41 HOSPITALS Doctors
TOTAL 336 30 295
 ER Development Plan

V-Pouch V-Connect (Wifi-Wingles)

• ER of Private Hospitals/Govt..
• 2 Private ER/TM
• 20 pouches /TM/Month
• Total for 7 months
• TM will cover 10 Drs Thrice in a month
• ER Private Hospitals/Govt.
• Total = 124 ERs (2/TM)
• Rs. 1500 recharge every month.

EMERGENCY ROOMS NO.

PRIVATE ER (DRS. 245) 79
GOVT. HOSPITALS ER 77
TOTAL 156
 Single Topic National CME
• Total 60 Drs Pan-Pakistan (2 CMEs)
• 1st CME GYN & GASTRI (30 Drs.)
• 2ND CME SURG & ONCO (30 Drs.)
• Kaghan Naran
• Presentation by one from VEMTIX NV Management Forum
• April-May
 Ward Presentations

• Total 72 presentation Nation wide in 9 months

• Presentation by Consultant/PM/BUM
• 1ST Go … GYN & Gastro
• 2ND Go… Oncology & SURG
 VEMTIX International CME Baku

• Total 30 Drs Nationwide

• Oncology = 10
• Gastro /PHY = 10
• Surgery = 10
• Presentation by VEMTIX NV Management Forum Consultant
• July-2020
 Safe Pakistan
(Capable Control Environment)
• 6 WARDS /ASM
• TOTAL 96 WARDS
• GASTRO, ONCO,GYNE & SURGERY

plantation Waste box Sanitizer Syring cutter

57
 V-Link
(PHOTO MOMENTS)

• Total 100 Drs. Nationwide

• 6 Drs/Region/9 MONTHS
• Oncology & Surg
 Awareness Campaign
• NVP & HG Ruler (Paramount
Books)

• Awareness Posters with

mountings

59
Give-Aways

60 MUSHTAQ
DR. MUHAMMAD
GM MKG & SALES
 PRICE COMPARISON

Ondansetron Price Injections

PACK
S.NO. BRAND NAME COMPANY NAME STRENGTHS SIZE MRP PRICE PER UNIT

1 ONSET PHARMEDIC 8MG 1 AMP 129.00 129.00

2 ADOSETRON SEARLE 8MG 5 AMP 745.00 149.00

3 ZOFRAN GSK 8MG 5 AMP 4525.66 905.13

4 ONDANSETRON SANDOZ 8MG 1 AMP 517.00 517.00

5 ENDTRON HORIZON 8MG 5 AMP 645.00 129.00

 PRICE COMPARISON

Ondansetron Price 8mg Tablets

PACK PRICE PER
S.NO. BRAND NAME COMPANY NAME STRENGTHS SIZE MRP UNIT

1 ONSET PHARMEDIC 8MG 10 TAB 375.00 37.50

2 ADOSETRON SEARLE 8MG 12 TAB 468.00 39.00

3 ZOFRAN GSK 8MG 10 TAB 3795.79 379.58

4 ENDTRON HORIZON 8MG 10 TAB 350.00 35.00

5 ONSERON INDUS 8MG 10 TAB 909.33 90.93